# Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

> **NCT00003600** · PHASE3 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 344 (actual)

## Conditions studied

- Anemia
- Breast Cancer
- Chronic Myeloproliferative Disorders
- Drug/Agent Toxicity by Tissue/Organ
- Leukemia
- Lung Cancer
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Precancerous Condition
- Small Intestine Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** epoetin alfa
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00003600
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-12
- **Primary completion:** 2001-12
- **Final completion:** 2010-01
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2016-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003600, "Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00003600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*